[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"perimenopausal-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:perimenopausal-disorder":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,75,107,139],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100646426","pelvic-floor-symptoms-across-menopausel-stages-100646426",false,"NCT07690137","Pelvic Floor Symptoms Across Menopausel Stages","Comparison of Lower Urinary Tract Symptoms, Bowel Function, and Sexual Health Across Menopausal Stages in Women","Inclusion Criteria:\n\n* Female\n* Age 40-65 years\n* Intact uterus and at least one ovary\n* Perimenopause or postmenopause according to STRAW+10 criteria\n* Able to read and understand Turkish\n\nExclusion Criteria:\n\n* Hormone replacement therapy within the previous 6 months\n* Oral contraceptive use\n* Antipsychotic medication use\n* Previous pelvic surgery\n* Neurological or systemic diseases affecting bladder or bowel function\n* Active urinary tract or vaginal infection\n* Pelvic radiotherapy or chemotherapy history\n* Active gynecological or urological malignancy\n* Alcohol or substance abuse during the previous year","FEMALE","40 Years","65 Years",{"count":20,"type":21},180,"ESTIMATED","OBSERVATIONAL","The menopausal transition is associated with substantial hormonal alterations that may adversely affect lower urinary tract function, bowel function, and sexual health. Although these symptoms are common, few studies have comprehensively evaluated all three pelvic floor compartments across different menopausal stages.\n\nThe aim of this study is to compare lower urinary tract symptoms, bowel symptoms, and female sexual function among women in the perimenopausal, early postmenopausal, and late postmenopausal stages. In addition, the relationship between menopausal stage and symptom severity will be investigated.",[25,26],"Menopause","Perimenopausal Disorder",[28,29,30,31],"Menopausal transition","Lower urinary tract symptoms","Bowel functions","Sexual functions","NOT_YET_RECRUITING","2026-07-07",{"date":35,"type":36},"2026-07-09","ACTUAL",{"date":38,"type":21},"2026-07-06",{"date":40,"type":21},"2026-10-06",{"name":42,"class":43},"Bezmialem Vakif University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":44},"100358755","phase-2-autologous-platelet-rich-plasma-prp-intra-ovarian-infusion-in-perimenopausal-women-100358755","NCT03951194","Autologous Platelet Rich Plasma (PRP) Intra Ovarian Infusion in Perimenopausal Women","Investigating Improvement of Ovarian Function Following Autologous PRP Intra-ovarian Infusion in Perimenopausal Women","PRP","Inclusion Criteria:\n\n* Women ≥40 years of age, presenting with cycle irregularities while fulfilling at least one of the respective two criteria: more than seven days difference in menstrual cycle duration between two consecutive cycles OR, presence of a menstrual cycle duration over sixty days and progressive elevation of FSH levels.\n* Discontinuation of any complementary\u002Fadjuvant treatment including hormone replacement, acupuncture, and botanotherapy, for at least three months prior to recruitment.\n* Willing to comply with study requirements\n\nExclusion Criteria:\n\n* Any pathological disorder related to reproductive system anatomy\n* Amenorrhea\n* Endometriosis\n* Adenomyosis\n* Fibroids and adhesions\n* Infections in reproductive system\n* Current or previous diagnosis of cancer in reproductive system\n* History of familiar cancer in reproductive system\n* Severe male factor infertility\n* Prior referral for PGT\n* Ovarian inaccessibility\n* Previous POI diagnosis -Endocrinological disorders (Hypothalamus-\n* Pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome)\n* BMI\\>30 kg\u002Fm2 or BMI\\\u003C18.5 kg\u002Fm2\n* Systematic autoimmune disorders",true,"50 Years",{"count":56,"type":21},100,"INTERVENTIONAL",[59,60],"PHASE2","PHASE3","Autologous PRP intra ovarian infusion may improve ovarian response and women's hormonal profile and may promote folliculogenesis in perimenopausal women.",[63,26,64],"Infertility, Female","Menstrual Cycle Abnormal","RECRUITING","2026-07-05",{"date":68,"type":36},"2026-07-08",{"date":70,"type":36},"2019-06-13",{"date":72,"type":21},"2028-07-30",{"name":74,"class":43},"Genesis Athens Clinic",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":53,"sex":16,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":57,"phases":86,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100548359","multimodal-program-for-climacteric-women-100548359","NCT06419972","Multimodal Program for Climacteric Women","Effectiveness of a Combined Education and Exercise Program on the Physical, Functional and Psychological Status of Climacteric Women.","Inclusion Criteria:\n\n* Women aged ≥45 years\n* Women in climacteric period\n\nExclusion Criteria:\n\n* Musculoskeletal, cognitive, infectious, neurological, or cardiorespiratory pathology impairing assessment or program completion.\n* Surgical intervention in lumbopelvic or gynecological region within the last 6 months.\n\nUndergoing oncological treatment.\n\n\\* Also included women with stable hormone replacement therapy for at least the last 6 months.","45 Years","85 Years",{"count":85,"type":21},115,[87],"NA","Your study seems to aim at emphasizing the significance of non-pharmacological and non-hormonal approaches in managing menopausal symptoms, particularly focusing on muscle training and education. This holistic approach acknowledges the importance of physical well-being, psychological support, and education to enhance women's quality of life during the menopausal transition.",[90,91,25,26],"Climacteric Syndrome","Postmenopausal Symptoms",[93,94,95,96],"perimenopause","climacteric","Postmenopause","women's health","2026-05-15",{"date":99,"type":36},"2026-05-19",{"date":101,"type":36},"2024-05-30",{"date":103,"type":21},"2026-12-28",{"name":105,"class":43},"University of Valencia",2,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":53,"sex":16,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":57,"phases":118,"briefSummary":119,"conditions":120,"keywords":124,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":44},"100556849","phase-2-the-muse-study-for-menopausal-arthralgia-100556849","NCT06530459","The MUSE Study for Menopausal Arthralgia","The MUScle Strengthening Exercises and Estrogen (MUSE) Randomized Controlled Trial for Menopausal Arthralgia","MUSE","INCLUSION CRITERIA:\n\n1. Patients with muscle stiffness and joint discomfort in various sites, including hands, knees, back, hips, and\u002For shoulders. Patients with pain in only one isolated joint would not be accepted.\n2. Arthralgia symptoms with onset, or has become worse, over the perimenopausal or early postmenopausal period (within 5 years of the menopause).\n3. Women should be at the menopause transition, less than or equal to 59 years old at the time of enrollment, or within 5 years of menopause whichever is earlier.\n\n   .\n4. Arthralgia for at least 3 months (pain lasting beyond normal injury healing period)\n5. Community-dwelling and able to ambulate independently.\n\nEXCLUSION CRITERIA:\n\n1. History of thrombo-embolic diseases, strokes, ischemic heart disease, dementia or psychiatric disorders, active liver disease or renal impairment, severe hyperlipidemia, gout, thyroid disease, systemic lupus erythematosus, rheumatoid arthritis, or other chronic inflammatory conditions.\n2. Pregnancy\n3. Non-adherence to national guidelines for breast cancer screening\n4. High risk for breast cancer\n5. Any joint surgery within the last 6 months\n6. Severe obesity: BMI\\>35\n7. Migraine with aura\n8. Poorly controlled diabetes\n9. Use of any form of female hormone supplementation within the past 12 weeks.\n10. High venous thromboembolism risk\n11. Current cholecystitis, fibroids, or undiagnosed abnormal uterine bleeding.\n12. Current smoker.\n13. History of endometrial, ovarian, peritoneal, cervical, breast or endocrine-dependent cancers.\n14. Receiving treatment for any form of cancer.\n15. History of fragility bone fractures within the 2 years.\n16. Any other cognitive, musculoskeletal, neurological, and cardiorespiratory condition affecting one's ability to participate in the study.","30 Years","59 Years",{"count":56,"type":21},[59,60],"The investigators plan to conduct a pilot 4-arm, randomized study comprising the following interventions: muscle strengthening exercises (MSE) alone, estrogen therapy (ET) alone, and a combination of MSE and ET, compared to usual care in women with menopausal arthralgia. The aim of this pilot study is to assess the feasibility, patient acceptability, and patient perspectives and logistics of delivering interventions, and practicability of outcome assessment tools in this 4-arm study over a 12-week period.",[121,25,26,122,123],"Arthralgia","Joint Pain","Postmenopausal Disorder",[125,126,127,128,129],"Menopausal hormone therapy","Muscle strength","Exercise","Randomized controlled trial","Midlife women","2024-07-26",{"date":132,"type":36},"2024-07-31",{"date":134,"type":21},"2024-08-01",{"date":136,"type":21},"2028-04",{"name":138,"class":43},"National University Hospital, Singapore",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":53,"sex":146,"minAge":147,"maxAge":4,"enrollmentInfo":148,"targetDuration":54,"studyType":22,"phases":4,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":44},"100553518","virtual-peri-menopause-registry-of-australia-100553518","NCT06487130","Virtual perI-\u002FMenopause Registry of AusTrALia","VITAL","Inclusion Criteria:\n\n* Any Australian over 18 years of age.\n\nExclusion Criteria:\n\n* None.","ALL","18 Years",{"count":149,"type":21},10000,"13 million (50.7%) Australians are born with ovaries, 14% (\\~3 million) are currently aged 40-59 yrs, \\& all such who live to midlife will experience menopause, defined as \\>12 months without a period. Peri-menopause (peri), typically occurs 5 yrs before menopause as hormone levels decrease. As with oestrogen, peri symptoms can affect every bodily system; e.g. depression\u002Fanxiety, diminished mental function, irregular periods, hot flushes, sleep problems, vaginal atrophy \\& urinary urgency. These symptoms are linked with lower quality of life \\& significantly higher work impairment; a third experiencing symptoms so severe as to impede daily life \\& increase risk of suicide. Lifetime increased risks of diabetes, heart disease, osteoporosis \\& dementia are also associated with menopause, yet it remains disconcertingly poorly studied.\n\nThe investigators propose to create a world-first, cutting-edge, consumer-driven, Virtual peri-\u002Fmenopause registry of AusTrALia (VITAL). The unique design will enable consumers to determine VITAL's questions, encourage secure revelation of private data e.g. vaginal \\& mental health symptoms, \\& to direct priorities for research, education, \\& health service improvements. VITAL will thus deliver optimal assessments of incidence, prevalence \\& impact.\n\nThe participating consumers, researchers, clinical specialists, policy makers, \\& modern virtual data infrastructure enable this unique \\& innovative registry design, future translation to improved community health, \\& promote awareness \\& collaborative synergies. Leveraging the investigators' critical range of expertise \\& ongoing feedback opportunities for both participants \\& stakeholder partnerships, the investigators will create a ground-breaking platform that:\n\n* empowers the consumer voice and priorities,\n* enables peri-\u002Fmenopause research to extend beyond existing niche focuses,\n* evidences the true impact of peri-\u002Fmenopause across the nation,\n* evolves healthcare services and outcomes, \\&\n* educates community, clinicians, \\& policy-makers. After Australian registry establishment, the investigators will expand VITAL to mirror it in other nations while still protecting individual's data the right way, but so all can learn \\& apply the best aspects of care from across the world.",[25,26,91,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168],"Health Knowledge, Attitudes, Practice","Healthy Aging","Health Care Utilization","Health Care Seeking Behavior","Mental Health Impairment","Mental Deterioration","Mental Health Issue","Osteoporosis, Postmenopausal","Diabetes Mellitus Risk","Diabetes Mellitus, Type 2","Dementia","Cardiovascular Diseases","Menopause Related Conditions","Hot Flashes","Hot Flushes Aggravated","Economic Burden","Social Stigma","2024-07-02",{"date":171,"type":36},"2024-07-05",{"date":173,"type":36},"2023-08-03",{"date":175,"type":21},"2073-08",{"name":177,"class":178},"Bespoke Clinical Research","INDUSTRY"]